Tamoxifen in early breast cancer

Lancet. 1998 Aug 1;352(9125):404. doi: 10.1016/S0140-6736(05)60502-8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Biomarkers / analysis
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • CD36 Antigens / analysis
  • Estrogen Antagonists / administration & dosage
  • Estrogen Antagonists / adverse effects
  • Estrogen Antagonists / therapeutic use*
  • Fatty Liver / chemically induced
  • Fatty Liver / pathology
  • Female
  • Flow Cytometry
  • Fluorescein-5-isothiocyanate
  • Fluorescent Dyes
  • Humans
  • Tamoxifen / administration & dosage
  • Tamoxifen / adverse effects
  • Tamoxifen / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Biomarkers
  • CD36 Antigens
  • Estrogen Antagonists
  • Fluorescent Dyes
  • Tamoxifen
  • Fluorescein-5-isothiocyanate